Vascular endothelial growth factor - A positive and negative regulator of tumor growth

Cancer Research

Volumn 70, Issue 3, 2010, Pages 863-867

  Vecchiarelli Federico, Laura M ^a   Cervi, David ^c   Haeri, Mehran ^a   Li, Yanmei ^a   Nagy, Andras ^b   Ben David, Yaacov ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CARCINOGENICITY; CELL MIGRATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; MICROENVIRONMENT; MOLECULAR MECHANICS; MURINE LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76249132913     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3592     Document Type: Review

References (29)

1. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-92.
2. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105: 1383-95.
3. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
4. Mayer EL, Lin NU, Burstein HJ. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 2007;5:314-23.
5. Hurwitz HI, Honeycutt W, Haley S, Favaro J. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin Colorectal Cancer 2006;6:66-9.
6. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008;456:809-13.
7. Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456:814-8.
8. Cervi D, Shaked Y, Haeri M, et al. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood 2007;109:2139-46.
9. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009;50:1329-35.
10. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12: 332-9.
11. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
12. Sung H-K, Park J-G, Iacovos M, et al. Dualistic effect of systemic vascular endothelial growth factor activity on tumor etiology. In preparation.
13. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
14. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 2005;117:701-8.
15. Schmid MC, Varner JA. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 2007;250:1-8.
16. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
17. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007:911-20.
18. + hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. Blood 2009;114:1831-41.
19. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999;34:879-86.
20. Kasuno K, Takabuchi S, Fukuda K, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 2004;279: 2550-8.
21. Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 2003;14:3470-81.
22. Walmsley SR, Chilvers ER, Whyte MK. Hypoxia, hypoxia inducible factor and myeloid cell function. Arthritis Res Ther 2009;11:219.
23. Zinkernagel AS, Johnson RS, Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med 2007;85: 1339-46.
24. 2 and the 3PHDs. How animal cells signal hypoxia to the nucleus. Cell 2001;107:1-3.
25. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
26. Xue Y, Religa P, Cao R, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A 2008;105:18513-8.
27. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
28. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.